# Biochanin A

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/biochanin-a
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 8 / 10
**Category:** Compound
**Also Known As:** 5,7-dihydroxy-4'-methoxyisoflavone, BCA, 4'-O-methylgenistein, Red clover isoflavone, Biochanin-A, 5,7-dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one

## Overview

Biochanin A is an isoflavonoid compound found in red clover that acts as a selective estrogen receptor modulator and phytoestrogen. It demonstrates potential anticancer and [neuroprotective effect](/ingredients/condition/cognitive)s through estrogen receptor binding and Sirt1 pathway activation.

## Health Benefits

• Potential anticancer effects demonstrated in preclinical studies on prostate, lung, and colon cancer cell lines at 10-100 μM concentrations (evidence: preclinical only)
• [Neuroprotective](/ingredients/condition/cognitive) properties shown in Parkinson's disease models via Sirt1 pathway activation (PMID 41483847, evidence: in vitro/in vivo animal models)
• [Anti-inflammatory](/ingredients/condition/inflammation) action through modulation of TNF-α, IL-1β, and NO in Alzheimer's models (evidence: animal studies only)
• [Mitochondrial function](/ingredients/condition/energy) support through regulation of biogenesis, fusion, and reduced apoptosis (evidence: preclinical models)
• Synergistic enhancement of chemotherapy/radiotherapy effects, particularly with temozolomide in glioblastoma at 70 μM (evidence: cell culture studies)

## Mechanism of Action

Biochanin A functions as a selective estrogen receptor modulator, binding to both ERα and ERβ receptors with preferential affinity for ERβ. It activates the Sirt1 (sirtuin 1) pathway, promoting cellular [longevity](/ingredients/condition/longevity) and neuroprotection. The compound also modulates apoptotic pathways and inhibits tumor cell proliferation through p53-mediated mechanisms.

## Clinical Summary

Current evidence for biochanin A comes primarily from preclinical studies, with no completed human clinical trials. In vitro studies show anticancer effects against prostate, lung, and colon cancer cell lines at concentrations of 10-100 μM. Animal studies demonstrate [neuroprotective](/ingredients/condition/cognitive) properties in Parkinson's disease models through Sirt1 activation. Human research is needed to establish clinical efficacy and optimal dosing protocols.

## Nutritional Profile

Biochanin A is a pure isoflavone compound (4-methylglenistin), not a whole food, so traditional macronutrient/micronutrient profiling does not apply. Molecular weight: 284.26 g/mol. Chemical formula: C16H12O5. It is a methylated isoflavone (O-methylated form of genistein) found naturally in red clover (Trifolium pratense) at approximately 1–5 mg/g dry weight, chickpeas (Cicer arietinum) at 0.1–0.5 mg/g, and fenugreek seeds at trace levels. Bioactive classification: phytoestrogen, polyphenol, isoflavone subclass. Estrogenic activity: weak estrogen receptor agonist (ERα and ERβ), with relative binding affinity approximately 100–1000-fold lower than 17β-estradiol. Bioavailability: oral bioavailability is limited (~10–20% estimated in animal models) due to extensive first-pass [metabolism](/ingredients/condition/weight-management); Biochanin A is partially demethylated to genistein by intestinal microbiota and liver enzymes (CYP1A2, CYP3A4), which may enhance or alter its biological activity. Peak plasma concentration following 40 mg oral dose in humans estimated at 0.5–1.5 μM. Half-life approximately 5–8 hours. Lipophilicity (LogP ≈ 2.8) suggests moderate membrane permeability. No fiber, protein, fat, or micronutrient content is applicable as this is an isolated bioactive compound. Preclinical effective concentrations range from 10–100 μM in cell-based assays, which substantially exceeds physiologically achievable plasma concentrations from dietary sources alone.

## Dosage & Preparation

No clinically studied dosage ranges are available due to lack of human trials. Preclinical studies used varying concentrations: 0.5-100 μM in cell cultures and 10-65 mg/kg in animal models. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Biochanin A appears well-tolerated in preclinical studies, but human safety data is limited. As a phytoestrogen, it may interact with hormone-sensitive medications and conditions including breast cancer, endometriosis, and uterine fibroids. Potential interactions with anticoagulant medications due to structural similarity to other isoflavonoids. Pregnant and breastfeeding women should avoid supplementation due to unknown effects on fetal development.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Biochanin A to date. All available evidence comes from preclinical studies including in vitro cell culture experiments and in vivo animal models, with researchers explicitly noting the need for human trials to establish safety and efficacy.

## Historical & Cultural Context

No specific historical or traditional medicine uses in systems like Ayurveda or TCM are documented in the available research. The compound is noted in red clover contexts for potential health maintenance, but without specific traditional timelines or systems specified.

## Synergistic Combinations

Red clover extract, Soy isoflavones, Quercetin, Resveratrol, Curcumin

## Frequently Asked Questions

### Is biochanin A safe for women with estrogen-sensitive cancers?

This is a critical safety concern given biochanin A's activity as a phytoestrogen and selective estrogen receptor modulator (SERM). It binds both ERα and ERβ receptors, with preferential affinity for ERβ. Because estrogen signaling can promote certain hormone-sensitive cancers, women with estrogen-receptor-positive breast cancer or similar conditions should avoid biochanin A supplementation unless under direct medical supervision. No human safety trials exist, making risk assessment speculative. Always consult an oncologist before use.

### Can biochanin A help with Parkinson's disease?

Preclinical evidence suggests biochanin A may offer neuroprotective benefits relevant to Parkinson's disease. In vitro and animal model studies (PMID 41483847) indicate it activates the Sirt1 pathway, which promotes neuronal survival and reduces oxidative stress—mechanisms implicated in Parkinson's pathology. It also supports mitochondrial function by regulating biogenesis and fusion while reducing apoptosis. However, no human clinical trials have been conducted, so these findings cannot yet be translated into clinical recommendations.

### What is the difference between biochanin A and formononetin?

Both biochanin A and formononetin are isoflavonoids found in red clover and belong to the same phytoestrogen class. The key structural difference is a methoxy group: biochanin A is the 4'-methoxy derivative of genistein, while formononetin is the 4'-methoxy derivative of daidzein. Biochanin A preferentially binds ERβ, whereas formononetin has distinct estrogenic activity profiles. Both have been studied for anticancer and cardioprotective effects, but biochanin A has more documented research in neuroprotection via the Sirt1 pathway.

### Does biochanin A have anti-inflammatory effects?

Yes, biochanin A demonstrates anti-inflammatory properties in preclinical models. Animal studies show it modulates key inflammatory markers including TNF-α, IL-1β, and nitric oxide (NO), all central mediators of neuroinflammation studied in Alzheimer's disease models. These effects are thought to occur through estrogen receptor signaling and Sirt1 pathway activation, which can suppress pro-inflammatory gene expression. However, these findings come exclusively from animal studies, and it is unknown whether equivalent effects occur in humans at achievable supplement doses.

### Can biochanin A be used alongside chemotherapy or radiation?

Preclinical cell culture studies suggest biochanin A may enhance the effectiveness of certain cancer treatments. Notably, at 70 μM concentrations, it demonstrated synergistic effects with temozolomide in glioblastoma cell lines. It has also been explored alongside radiotherapy in preclinical cancer models. However, these concentrations far exceed what standard supplementation achieves in humans, and no clinical trials exist. Patients undergoing chemotherapy or radiotherapy must consult their oncologist before adding any supplement, as interactions could alter treatment outcomes.

### What are the known side effects of biochanin A?

No formal human safety or side-effect data exists for biochanin A supplementation, as no clinical trials have been conducted. Based on its mechanism as a phytoestrogen and SERM, theoretical concerns include hormonal disruption, particularly in individuals with hormone-sensitive conditions. High-dose preclinical studies used 10–65 mg/kg in animal models and 10–100 μM in cell cultures, concentrations not directly translatable to human exposure. Until human safety studies are available, supplementation should be approached cautiously under healthcare provider guidance.

### Does biochanin A affect prostate health?

Preclinical studies have examined biochanin A's potential role in prostate cancer, with cell culture experiments at 10–100 μM concentrations showing inhibition of prostate cancer cell proliferation. The proposed mechanism involves p53-mediated apoptotic pathways and estrogen receptor modulation, as ERβ is expressed in prostate tissue and associated with anti-proliferative signaling. While these findings are encouraging, they are limited to laboratory settings. No human studies confirm these effects, and biochanin A cannot currently be recommended as a prostate health intervention.

### Is biochanin A the same as red clover extract?

No, biochanin A is one of several active isoflavonoids present in red clover (Trifolium pratense), not equivalent to red clover extract itself. Red clover extract typically contains a mixture of isoflavones including biochanin A, formononetin, daidzein, and genistein. Standardised red clover supplements vary considerably in their biochanin A content. If targeting biochanin A's specific ERβ-preferential activity or Sirt1 pathway effects, a product standardised to biochanin A content would be more appropriate than a generic red clover extract.

### What are the main health benefits of biochanin A?

Biochanin A, an isoflavonoid from red clover, shows several potential benefits in preclinical research. These include anticancer activity against prostate, lung, and colon cancer cell lines, neuroprotection via Sirt1 pathway activation, anti-inflammatory effects through suppression of TNF-α, IL-1β, and nitric oxide, and mitochondrial support through enhanced biogenesis and reduced apoptosis. Importantly, all evidence comes from cell culture and animal studies. No human clinical trials have been conducted, so these benefits cannot yet be confirmed in people.

### What foods are high in biochanin A?

Biochanin A is predominantly found in red clover (Trifolium pratense), which is the richest dietary source and the basis for most research on this compound. It is also present in smaller amounts in other legumes such as chickpeas, peanuts, and certain bean varieties. Red clover supplements and isoflavone extracts are the most common commercial sources used in research contexts. Dietary intake from food alone is generally modest compared to the concentrations used in preclinical studies.

### How much biochanin A should I take per day?

There is currently no established safe or effective human dosage for biochanin A, as no clinical trials have been performed. Preclinical research used concentrations of 0.5–100 μM in cell cultures and 10–65 mg/kg in animal models, which do not directly translate to human dosing recommendations. Red clover supplements typically contain mixed isoflavones including biochanin A, but standardised biochanin A dosing remains undefined. Always consult a qualified healthcare provider before starting supplementation.

### Can biochanin A help with Alzheimer's disease?

Preclinical animal studies suggest biochanin A may have anti-inflammatory effects relevant to Alzheimer's disease, specifically by modulating TNF-α, IL-1β, and nitric oxide — key inflammatory mediators implicated in neurodegeneration. These findings are based on animal models only and have not been replicated in human trials. While the mechanisms are plausible, it would be premature to recommend biochanin A for Alzheimer's prevention or treatment without supporting clinical evidence.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*